CN103483407A - Composite solvent for extractive crystallization of erythromycin thiocyanate and extractive crystallization method - Google Patents
Composite solvent for extractive crystallization of erythromycin thiocyanate and extractive crystallization method Download PDFInfo
- Publication number
- CN103483407A CN103483407A CN201310468714.0A CN201310468714A CN103483407A CN 103483407 A CN103483407 A CN 103483407A CN 201310468714 A CN201310468714 A CN 201310468714A CN 103483407 A CN103483407 A CN 103483407A
- Authority
- CN
- China
- Prior art keywords
- matachrom
- solvent
- erythromycin
- extractive crystallization
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002904 solvent Substances 0.000 title claims abstract description 35
- 238000002425 crystallisation Methods 0.000 title claims abstract description 32
- 230000008025 crystallization Effects 0.000 title claims abstract description 20
- PGNYNCTUBKSHHL-UHFFFAOYSA-N 2,3-diaminobutanedioic acid Chemical compound OC(=O)C(N)C(N)C(O)=O PGNYNCTUBKSHHL-UHFFFAOYSA-N 0.000 title abstract 7
- 239000002131 composite material Substances 0.000 title abstract 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 54
- 229960003276 erythromycin Drugs 0.000 claims abstract description 36
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000000605 extraction Methods 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000001335 aliphatic alkanes Chemical class 0.000 claims abstract description 12
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 12
- SOIFLUNRINLCBN-UHFFFAOYSA-N ammonium thiocyanate Chemical compound [NH4+].[S-]C#N SOIFLUNRINLCBN-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 7
- 230000003068 static effect Effects 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229930006677 Erythromycin A Natural products 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 2
- 239000003513 alkali Substances 0.000 abstract description 2
- 238000004945 emulsification Methods 0.000 abstract description 2
- 238000004821 distillation Methods 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 4
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- MQTOSJVFKKJCRP-HHZDEWPHSA-N Azythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@H]([C@@]([C@H](O)[C@H](C)N(C)C[C@@H](C)C[C@](C)(O)[C@@H](O[C@@H]2[C@H]([C@@H](C[C@H](C)O2)N(C)C)O)[C@@H]1C)(C)O)CC)[C@@H]1C[C@](C)(OC)[C@H](O)[C@@H](C)O1 MQTOSJVFKKJCRP-HHZDEWPHSA-N 0.000 description 1
- MWFRKHPRXPSWNT-UHFFFAOYSA-N Erythromycin-C Natural products CC1C(OC2C(C(CC(C)O2)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C(C)C1OC1CC(C)(O)C(O)C(C)O1 MWFRKHPRXPSWNT-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229950002013 berythromycin Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- IDRYSCOQVVUBIJ-PPGFLMPOSA-N erythromycin B Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 IDRYSCOQVVUBIJ-PPGFLMPOSA-N 0.000 description 1
- CLQUUOKNEOQBSW-KEGKUKQHSA-N erythromycin D Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 CLQUUOKNEOQBSW-KEGKUKQHSA-N 0.000 description 1
- PRUSTPADOGZAML-UHFFFAOYSA-N erythromycin E Natural products O1C2C(C)C(OC3C(C(CC(C)O3)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C2COC21CC(C)(OC)C(O)C(C)O2 PRUSTPADOGZAML-UHFFFAOYSA-N 0.000 description 1
- PRUSTPADOGZAML-LMXGZOGMSA-N erythromycin E Chemical compound C([C@H]1C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@@H](C)[C@@H]1O1)(C)O)CC)O[C@]21C[C@@](C)(OC)[C@@H](O)[C@H](C)O2 PRUSTPADOGZAML-LMXGZOGMSA-N 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a composite solvent for extractive crystallization of erythromycin thiocyanate and an extractive crystallization method. The composite solvent is mixed from 20%-80% of C6-12 alkane and 20%-80% of C8-10 benzene homolog. The composite solvent provided by the invention has the following advantages: extremely low solubility in water to reduce loss in the extraction process, small density and little emulsification during extraction and back extraction processes to facilitate separation, and low price to reduce production cost of erythromycin thiocyanate. The two selected solvents have high stability; residues in the solvent can be removed through acid, alkali and oxidation treatment, without consuming a large amount of steam for distillation treatment; and the treated solvent can be reused. Through the extraction and back extraction by the solvent provided by the invention, crystallization of erythromycin thiocyanate in water phase can be realized, and the quality of erythromycin thiocyanate is obvious better than that of erythromycin thiocyanate from solvent phase crystallization. Erythromycin A in the erythromycin thiocyanate provided by the invention reaches 84-86%.
Description
Technical field
The invention belongs to technical field of biological fermentation, particularly relate to a kind of double solvent and extractive crystallization method for Matachrom extractive crystallization.
Background technology
Erythromycin is a class macrolide antibiotics, mainly comprises 6 kinds of components such as Erythromycin A, berythromycin, Erythromycin C, Erythromycin D, Erythromycin E and ErF, and wherein the antibacterial activity with Erythromycin A is the strongest.Matachrom is a class macrolide antibiotics, is the thiocyanate-of erythromycin.Matachrom is veterinary drug, for the infection of gram-positive microorganism and mycoplasma; More as initial feed for the synthesis of macrolide antibiotics such as erythromycin, Roxithromycin, Azythromycin, clarithromycins.At present, the preparation of Matachrom is mainly to adopt two membrane process and extraction process, the solvent that wherein extraction process is used is mostly N-BUTYL ACETATE or the solvent that contains N-BUTYL ACETATE, in N-BUTYL ACETATE water, solubleness reaches 1%, in extraction process, solvent loss is large, not only increased production cost, and a large amount of N-BUTYL ACETATEs enters waste water and is difficult to process.
Summary of the invention
Purpose of the present invention just is to overcome the defect of above-mentioned prior art, provides a kind of solubleness low, and solvent loss is little, and cost is low, is convenient to the Matachrom extractive crystallization double solvent of processing;
Another object of the present invention is to provide utilizes above-mentioned double solvent to carry out the extractive crystallization method of Matachrom.
The technical scheme taked for achieving the above object is:
A kind of Matachrom extractive crystallization double solvent, it is characterized in that being mixed by the benzene homologue of the C8 of 20%～80% C6～12 alkane and 20%～80%～10.
Described C6～12 alkane comprise straight-chain paraffin and naphthenic hydrocarbon, comprise hexanaphthene, normal hexane, heptane, octane, nonane, decane, undecane, dodecane.Benzene homologue is dimethylbenzene, inclined to one side triphen, isopropyl benzene etc.
A kind of Matachrom extractive crystallization method, it is characterized in that its processing step is: the double solvent that at first adopts the benzene homologue by the C8 of 10%～90% C6～12 alkane and 10%～90%～10 to mix is extracted erythromycin filtrate, static separating obtained double solvent extraction liquid is after saturated NaCl solution dehydrates, activated carbon decolorizing, filtration, add pure water, and then stripped with acetum, add ammonium thiocyanate solution to stream in stripping solution and carry out crystallization, rear separation, drip washing, drying obtain Matachrom.
The volume ratio of described erythromycin filtrate and double solvent is 10:1～5.
Described extraction conditions is: 30～40 ℃ of extraction temperature, extraction pH10.0～11.0.
Described reextraction condition is: acetum concentration is 10～20%, 15～40 ℃ of reextraction temperature, pH4.5～5.5.
Described ammonium thiocyanate concentration of polymer solution is 10%～50%, and its consumption adds 2.4～4ml ammonium thiocyanate solution according to every 100ml strip liquor stream, and stream adds 1.5～3.5 hours time.
The processing of the hydrochloric acid soln that described used double solvent is first 1～10% by concentration, dividing the Xiang Houzai concentration of anhydrating is that 1～10% buck is processed, and finally uses 0.1～1% hydrogen peroxide to be processed, the solvent after processing can reuse.
Matachrom extractive crystallization of the present invention is compared with N-BUTYL ACETATE and is had following technical superiority with double solvent:
The first, in water, solubleness is extremely low, is only 1 ‰, is 1/10th of N-BUTYL ACETATE, thereby loss reduces in extraction process.
The second, density is little, extracts and return the emulsification of extraction process little, is easy to separate.
Three, solvent is cheap, can reduce the production cost of Matachrom.
Four, two kinds of solvent stabilities that the present invention selects are high, by acid, alkali and oxide treatment, can remove residue in solvent, without consuming a large amount of steam, distill processing, and the solvent after processing can reuse.
The the 5th: by solvent of the present invention, extracted and return extraction, the technique of realization Matachrom of crystallization in water, the Matachrom quality is significantly better than the Matachrom of solvent phase crystallization, and in Matachrom of the present invention, Erythromycin A reaches between 84～86%.
Embodiment
Further describe the present invention by following examples, and do not limit the present invention in any way, under the prerequisite that does not deviate from technical solution of the present invention, within any change that those of ordinary skills made for the present invention easily realize or change all will fall into claimed range of the present invention.
Embodiment 1
200ml(alkane 40%) decane and 300ml(benzene homologue 60%) the isopropyl benzene mixing, join in 4000ml erythromycin filtrate, in filtrate, Erythromycin A concentration is 0.45%, add liquid caustic soda and adjust pH to 10.9,30 ℃～40 ℃ extractions, static separation obtains the double solvent extraction liquid that 500ml Erythromycin A concentration is 3.2%, the erythromycin extraction liquid is after supersaturation NaCl solution dehydrates, activated carbon decolorizing, filtration, add the 500ml purified water also with 15% vinegar acid for adjusting pH to 4.9, staticly separate to such an extent that 500ml returns extraction liquid, the reextraction temperature is controlled at 15 ℃～40 ℃.Returning extract flow adds 10% ammonium thiocyanate 20ml(stream and adds 1.5～3.5 hours time), complete crystallization, purified water drip washing after separating, drying, obtain Matachrom 16.4g, moisture content 4.4%, the red middle Erythromycin A content 84.6% of sulphur.
Embodiment 2
200ml(alkane 40%) methylcyclohexane and 300ml(benzene homologue 60%) triphen mixing partially, join in 4000ml erythromycin filtrate, in filtrate, Erythromycin A concentration is 0.4%, add liquid caustic soda and adjust pH to 10.8,30 ℃～40 ℃ extractions, static separation obtains the double solvent extraction liquid that 500ml Erythromycin A concentration is 3.0%, the erythromycin extraction liquid is after supersaturation NaCl dehydration, activated carbon decolorizing, filtration, add the 500ml purified water and 10% vinegar acid for adjusting pH to 4.8 is arranged, staticly separate to such an extent that 500ml returns extraction liquid, the reextraction temperature is controlled at 15 ℃～40 ℃.Returning extract flow adds 20% ammonium thiocyanate 14ml(stream and adds 1.5～3.5 hours time), complete crystallization, purified water drip washing drying after separating, obtain Matachrom 15.8g, moisture content 4.6%, the red middle Erythromycin A content 84.9% of sulphur.
Embodiment 3
300ml(alkane 60%) nonane and 200ml(benzene homologue 40%) the dimethylbenzene mixing, join in 4000ml erythromycin filtrate, in filtrate, Erythromycin A concentration is 0.35%, add liquid caustic soda and adjust pH to 10.5,30 ℃～40 ℃ extractions,, static separation obtains the double solvent extraction liquid that 500ml Erythromycin A concentration is 2.8%, the erythromycin extraction liquid, after supersaturation NaCl dehydration, activated carbon decolorizing, filtration, adds the 500ml purified water and 20% vinegar acid for adjusting pH to 5.3 is arranged.Staticly separate to such an extent that 500ml returns extraction liquid, the reextraction temperature is controlled at 15 ℃～40 ℃.Returning extract flow adds 40% ammonium thiocyanate 12ml(stream and adds 1.5～3.5 hours time), complete crystallization, purified water drip washing drying after separating, obtain Matachrom 13.6g, moisture content 4.5%, the red middle Erythromycin A content 84.2% of sulphur.
Embodiment 4
100ml(alkane 20%) hexanaphthene and 400ml(benzene homologue 80%) the butylbenzene mixing, join in 4000ml erythromycin filtrate, in filtrate, Erythromycin A concentration is 0.45%, add liquid caustic soda and adjust pH to 10.8,30 ℃～40 ℃ extractions, static separation obtains the double solvent extraction liquid that 500ml Erythromycin A concentration is 3.5%, and the erythromycin extraction liquid, after supersaturation NaCl dehydration, activated carbon decolorizing, filtration, adds the 500ml purified water and 15% vinegar acid for adjusting pH to 5.3 is arranged.Staticly separate to such an extent that 500ml returns extraction liquid, the reextraction temperature is controlled at 15 ℃～40 ℃.Returning extract flow adds 25% ammonium thiocyanate 14ml(stream and adds 1.5～3.5 hours time), complete crystallization, purified water drip washing drying after separating, obtain Matachrom 17.6g, moisture content 4.9%, the red middle Erythromycin A content 85.0% of sulphur.
Embodiment 5
400ml(alkane 80%) octane and 100ml(benzene homologue 20%) the butylbenzene mixing, join in 4000ml erythromycin filtrate, in filtrate, Erythromycin A concentration is 0.43%, add liquid caustic soda and adjust pH to 10.5,30 ℃～40 ℃ extractions,, static separation obtains the double solvent extraction liquid that 500ml Erythromycin A concentration is 3.2%, the erythromycin extraction liquid, after supersaturation NaCl dehydration, activated carbon decolorizing, filtration, adds the 500ml purified water and 14% vinegar acid for adjusting pH to 5.3 is arranged.Staticly separate to such an extent that 500ml returns extraction liquid, the reextraction temperature is controlled at 15 ℃～40 ℃.Returning extract flow adds 50% ammonium thiocyanate 14ml(stream and adds 1.5～3.5 hours time), complete crystallization, purified water drip washing drying after separating, obtain Matachrom 16.6g, moisture content 4.4%, the red middle Erythromycin A content 86.0% of sulphur.
Claims (8)
1. a Matachrom extractive crystallization double solvent, it is characterized in that being mixed by the benzene homologue of the C8 of 20%～80% C6～12 alkane and 20%～80%～10.
2. according to Matachrom extractive crystallization double solvent claimed in claim 1, it is characterized in that described C6～12 alkane comprise straight-chain paraffin and naphthenic hydrocarbon.
3. a Matachrom extractive crystallization method, it is characterized in that its processing step is: the double solvent that at first adopts the benzene homologue by the C8 of 10%～90% C6～12 alkane and 10%～90%～10 to mix is extracted erythromycin filtrate, static separating obtained double solvent extraction liquid is after saturated NaCl solution dehydrates, activated carbon decolorizing, filtration, add pure water, and then stripped with acetum, add ammonium thiocyanate solution to stream in stripping solution and carry out crystallization, rear separation, drip washing, drying obtain Matachrom.
4. according to Matachrom extractive crystallization method claimed in claim 3, it is characterized in that: the volume ratio of described erythromycin filtrate and double solvent is 10:1～5.
5. according to Matachrom extractive crystallization method claimed in claim 3, it is characterized in that described extraction conditions is: 30～40 ℃ of extraction temperature, extraction pH10.0～11.0.
6. according to Matachrom extractive crystallization method claimed in claim 3, it is characterized in that described reextraction condition is: acetum concentration is 10～20%, 15～40 ℃ of reextraction temperature, pH4.5～5.5.
7. according to Matachrom extractive crystallization method claimed in claim 3, it is characterized in that described ammonium thiocyanate concentration of polymer solution is 10%～50%, its consumption adds 2.4～4ml ammonium thiocyanate solution according to every 100ml strip liquor stream, and stream adds 1.5～3.5 hours time.
8. according to Matachrom extractive crystallization method claimed in claim 3, it is characterized in that: the processing of the hydrochloric acid soln that described used double solvent is first 1～10% by concentration, dividing the Xiang Houzai concentration of anhydrating is that 1～10% buck is processed, finally use 0.1～1% hydrogen peroxide to be processed, the solvent after processing can reuse.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310468714.0A CN103483407B (en) | 2013-10-10 | 2013-10-10 | A kind of Matachrom extractive crystallization double solvent and extractive crystallization method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310468714.0A CN103483407B (en) | 2013-10-10 | 2013-10-10 | A kind of Matachrom extractive crystallization double solvent and extractive crystallization method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103483407A true CN103483407A (en) | 2014-01-01 |
| CN103483407B CN103483407B (en) | 2015-11-18 |
Family
ID=49824049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310468714.0A Active CN103483407B (en) | 2013-10-10 | 2013-10-10 | A kind of Matachrom extractive crystallization double solvent and extractive crystallization method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103483407B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105348340A (en) * | 2015-11-27 | 2016-02-24 | 宁夏启元药业有限公司 | Preparation method of erythromycin thiocyanate |
| CN105777827A (en) * | 2014-12-15 | 2016-07-20 | 宁夏启元药业有限公司 | Extraction method of high-purity erythromycin E |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1367842A (en) * | 1963-07-24 | 1964-07-24 | Pierrel Spa | Process for making a new water-soluble erythromycin salt |
| US3637654A (en) * | 1969-04-03 | 1972-01-25 | Abbott Lab | Purification of erythromycin thiocyanate |
| CN1050014A (en) * | 1989-07-18 | 1991-03-20 | 阿托化学公司 | Preparation 1, the method for two (4-the chloro-phenyl-)-trichloro-ethyl alcohol of 1- |
| CN1488632A (en) * | 2002-08-05 | 2004-04-14 | 中国石油股份有限公司 | Purification method for obtaining high-purity pyromellitic dianhydride |
| CN1680456A (en) * | 2004-04-01 | 2005-10-12 | 通用电气公司 | Electroactive polymers, devices and methods made therefrom |
| CN101133049A (en) * | 2005-03-03 | 2008-02-27 | 埃斯特维化学股份有限公司 | Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol |
| CN101624412A (en) * | 2008-07-10 | 2010-01-13 | 刘力 | Derivative of macrolides, method for preparing same and application thereof |
| CN102408462A (en) * | 2011-12-02 | 2012-04-11 | 伊犁川宁生物技术有限公司 | Preparation method of erythromycin thiocyanate |
| CN102844306A (en) * | 2010-04-20 | 2012-12-26 | 先正达参股股份有限公司 | Process for preparation of pyrazole carboxylic acid amide |
| CN102858749A (en) * | 2010-04-20 | 2013-01-02 | 先正达参股股份有限公司 | Process for the preparation of pyrazole carboxylic acid amides |
-
2013
- 2013-10-10 CN CN201310468714.0A patent/CN103483407B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1367842A (en) * | 1963-07-24 | 1964-07-24 | Pierrel Spa | Process for making a new water-soluble erythromycin salt |
| US3637654A (en) * | 1969-04-03 | 1972-01-25 | Abbott Lab | Purification of erythromycin thiocyanate |
| CN1050014A (en) * | 1989-07-18 | 1991-03-20 | 阿托化学公司 | Preparation 1, the method for two (4-the chloro-phenyl-)-trichloro-ethyl alcohol of 1- |
| CN1488632A (en) * | 2002-08-05 | 2004-04-14 | 中国石油股份有限公司 | Purification method for obtaining high-purity pyromellitic dianhydride |
| CN1680456A (en) * | 2004-04-01 | 2005-10-12 | 通用电气公司 | Electroactive polymers, devices and methods made therefrom |
| CN101133049A (en) * | 2005-03-03 | 2008-02-27 | 埃斯特维化学股份有限公司 | Process for the preparation of optically active derivatives of 2-(2-pyridylmethylsulfinyl)-benzimidazole via inclusion complex with 1,1'-binaphthalene-2, 2'diol |
| CN101624412A (en) * | 2008-07-10 | 2010-01-13 | 刘力 | Derivative of macrolides, method for preparing same and application thereof |
| CN102844306A (en) * | 2010-04-20 | 2012-12-26 | 先正达参股股份有限公司 | Process for preparation of pyrazole carboxylic acid amide |
| CN102858749A (en) * | 2010-04-20 | 2013-01-02 | 先正达参股股份有限公司 | Process for the preparation of pyrazole carboxylic acid amides |
| CN102408462A (en) * | 2011-12-02 | 2012-04-11 | 伊犁川宁生物技术有限公司 | Preparation method of erythromycin thiocyanate |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105777827A (en) * | 2014-12-15 | 2016-07-20 | 宁夏启元药业有限公司 | Extraction method of high-purity erythromycin E |
| CN105348340A (en) * | 2015-11-27 | 2016-02-24 | 宁夏启元药业有限公司 | Preparation method of erythromycin thiocyanate |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103483407B (en) | 2015-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69110392T2 (en) | METHOD FOR SEPARATING IMPURITIES FROM AQUEOUS SOLUTIONS OF ROHETHANOL. | |
| US7056439B2 (en) | Process for producing 1, 3-propanediol | |
| CN103588837B (en) | Tylosin tartrate or Webel Tylan Premix is extracted from anti-stripping agent | |
| CN102952000A (en) | Refining process of biodiesel byproduct crude glycerol | |
| WO2015109901A1 (en) | Extracting agent for treating coking wastewater | |
| CN109942492A (en) | A kind of caprolactam refining technique | |
| CN103044508A (en) | Method for extracting crystallized erythromycin thiocyanate from fermentation liquid | |
| CN104761528B (en) | A method of natural VE is extracted with ion liquid abstraction agent | |
| CN103483407B (en) | A kind of Matachrom extractive crystallization double solvent and extractive crystallization method | |
| CN103723744A (en) | Method for extraction of high purity sodium thiocyanate from desulfurization waste liquid or desulfurization liquid mixed salt | |
| CN109651308A (en) | A kind of purification process of 5 hydroxymethyl furfural | |
| CN103772186A (en) | Refining method of fermented organic acid | |
| CN104098495A (en) | Method for improving caprolactam refining process | |
| CN105985315A (en) | Method for extracting nicotine from tobacco waste | |
| EP3802505A1 (en) | Preparation of hmf catalyzed by a mixture of salt and acid | |
| CN112174856B (en) | Purification production process of organic sulfonic acid | |
| CN103275151B (en) | A kind of process for purification of Matachrom | |
| CN1088055C (en) | Process for extracting alpha-or omege-alkadicarboxylic acid from fermented liquid and refining it | |
| CN113980070B (en) | A kind of purification method of hydrophilic mannose erythritol lipid | |
| CN106745444B (en) | Treatment method of T acid industrial wastewater | |
| CN113801003B (en) | Industrial extraction method of cannabidiol | |
| CN115974682A (en) | Clean production method for separating and purifying succinic acid by using neutral fermentation liquor | |
| CN103923130B (en) | Be separated the method for glucose and xylose in stalk fibre enzymolysis solution | |
| CN115260005A (en) | Method for purifying and extracting cannabidiol and application | |
| CN103772454A (en) | Refining method for clindamycin phosphate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |